The US Food and Drug Administration (FDA) has granted approval for a groundbreaking new indication for Wegovy (semaglutide) injection, a medication aimed at reducing the risk of cardiovascular death, heart attack, and stroke in adults grappling with both cardiovascular disease and either obesity or overweight
Apparao, K
Because of its high prevalence in conjunction with obesity, diabetes, and insulin resistance, NAFLD has been increasingly appreciated as a hepatic manifestation of metabolic syndrome and is the leading cause of death from liver disease in the United States 1,2,3
Anyone researching peptide therapies should rely on credible scientific sources and prioritize safety, product quality, and professional guidance
Take our free assessment quiz and let us help you reach your goals, wherever your travels may take you
But apparently the CEG members expect their audience of primary care vets to unquestionably accept this advice despite the fact that it is not based upon any evidence, and more importantly, despite the fact that it expressly contradicts peer-reviewed, evidence-based, published research to the contrary